Research into leading cause of stillbirth awarded £2.4 million funding
Researchers and clinicians at the Trust have been awarded over £2.4 million to investigate the best technique to manage poor growth in babies during the later stages of pregnancy.
The study will be led by the head of fetal medicine at Imperial College Healthcare NHS Trust, Professor Christoph Lees, who is also part of the Department of Metabolism, Digestion and Reproduction at Imperial College London.
Fetal growth restriction (FGR) is caused mainly by problems with blood flow through the placenta, which supplies oxygen and blood to the baby. These problems can slow or stop the fetus’ growth and lead to health complications. Babies with FGR often have to be delivered prematurely.
FGR can also lead to stillbirth and accounts for half of the cases of stillbirth in the UK. The new international study, funded by the National Institute for Health Research (NIHR), will investigate the best time to deliver babies who are diagnosed with FGR in late preterm pregnancy.
Currently there is no consensus for the optimal timing of delivering such babies in late preterm pregnancy (32-36 weeks). Doctors make their decisions by carefully balancing the risks of keeping the baby in the womb versus the risks of preterm delivery.
The Trial of Randomised Umbilical and Fetal Flow in Europe 2 (TRUFFLE 2) study aims to help clarify the decision process and move towards harmonisation of practice across Europe.
Professor Lees said: “Poor growth of babies during pregnancy affects 3 in 100 pregnancies and can cause anxiety for women and their loved ones, as they have to be closely monitored throughout their pregnancy and deliver their babies earlier than expected.
“Although we have different tests for monitoring babies with FGR, there is no real consensus for when babies with FGR should be delivered in the later stages of pregnancy, leading to varying outcomes for women and their babies following delivery and beyond. This trial could have real implications on outcomes for women and their babies and reduce the long-term complications associated with FGR.”
Professor Lees and his team will investigate whether it is possible to calculate which babies with FGR should be delivered early by monitoring an aspect of the fetus’s blood flow.
Cerebral redistribution is a condition where blood flow is prioritised to a baby’s brain at the expense of other organs, due to problems with the placenta. When this occurs, the fetus adapts its circulation to preserve oxygen and supply nutrients to the brain. However, this can lead to life threatening complications as other major organs are deprived of oxygen and nutrients. Previous studies have shown that fetuses with signs of cerebral redistribution have a higher risk of developing neurodevelopmental disorders.
The team will recruit over 1500 pregnant women from 11 UK hospitals, including Imperial College Healthcare NHS Trust, and 42 hospitals across Europe. The researchers will follow the women from 32 weeks onward and their babies will be monitored for signs of cerebral redistribution.
If babies show signs of cerebral redistribution, women will be randomly allocated for either immediate delivery or close monitoring, with delivery once there are other signs that might prompt concern. The team will also follow up with the babies over two years to see how they develop following delivery and their neurodevelopmental outcomes.
The researchers will compare this method with other FGR monitoring techniques such as the umbilical artery Doppler test, which checks blood flow through the placenta.
The TRUFFLE 2 Study is the follow up to the TRUFFLE 1 study, which informed national and international guidelines for managing FGR during earlier stages of pregnancy. It is an example of the work carried out by the Academic Health Science Centre (AHSC), a joint initiative between Imperial College Healthcare NHS Trust, Imperial College London and three other NHS Trusts and research organisations in London. It aims to transform healthcare by turning scientific discoveries into medical advances to benefit local, national and global populations in as fast a time frame as possible.
